xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

378

KUANetal.

∙ Characterization of long-term adverse effects of treat ment, ranging from secondary conditions that may have significant health risks (e.g., radiation necrosis, second primary) to those with QOL implications (e.g., sinusitis, chronic rhinitis). ∙ Development of optimal long-term surveillance pro tocols based on histopathology, and which imaging modalities (e.g., MRI, PET) are most appropriate at which intervals. XXXV CONCLUSION ICSNT represents an unprecedented, concerted effort to bring together experts from around the world and across disciplines to synthesize the current evidence of sinonasal tumor care, focusing on essential topics such as general principles, benign and malignant histopathologies, QOL, and survivorship. The evidence level is overall highly het erogeneous, with many noted areas of additional investi gation needed, and would likely benefit from a team-based approach given the rarity of many pathologies. As our understanding deepens and there is increased recogni tion of this class of diseases, new questions and avenues of investigation will be generated, with future versions of ICSNT again focusing on critical updates and major paradigm shifts. We sincerely hope that ICSNT serves as an informative and useful resource for clinicians of all train ing levels and areas of expertise who are united across the front to face the challenges of sinonasal tumors. ACKNOWLEDGMENTS This research was supported (in part) by the Intramu ral Research Program of the Center for Cancer Research, National Cancer Institute (N. R. London Jr.). The authors thank Mary Jo Tutchko for administrative support and Jen nifer C. Westrick, MSLIS, AHIP for her contribution to the search strategy. CONFLICT OF INTEREST STATEMENT E. C. Kuan: Consultant for Stryker and 3-D Matrix; royal ties from Springer Books N. D. Adappa: Consultant for Acclarent D. M. Beswick: Grant support from Cystic Fibrosis Foun dation, International Society of Inflammation and Allergy of the Nose, and the CORE/Sue Ann and John L. Weinberg Foundation; honoraria and consulting fees on medicolegal cases and at Garner Health (equity) N. R. London Jr.: Grant funding from Merck Sharp & Dohme, LLC regarding HPV-related sinonasal malignan cies; holds stock in Navigen Pharmaceuticals C. S. Betz: Consultant for Medtronic, Bristol-Myers Squibb, and Brainlab

B. S. Bleier: Consultant for Olympus, Karl Storz, Medtronic, and Stryker; equity interest in SoundHealth, Diceros Therapeutics, and Inquis Medical; royalties from Thieme R. K. Chandra: Consultant for Olympus, Lyra Therapeu tics, Optinose, and Regeneron A. U. Luong: Current PI on clinical trials for Sanofi; consultant to ENTvantage, Lyra Therapeutics, Maxwell Biosciences, Medtronic, SoundHealth, and Stryker S. N. Markovic: Grant funding from BMS and Sorrento Pharma Z. M. Patel: Consultant/advisory board member for Medtronic, Optinose, Dianosic, Regeneron/Sanofi, Ethicon Johnson & Johnson, Mediflix, Consumer Medical, and Wyndly; equity: Olfera Therapeutics A. J. Psaltis: Consultant for Medtronic, ENT Tech nologies, and Fusetech; speakers bureau with Sequiris; shareholder with Chitogel P. Schafhausen: Consultant with Bristol-Myers Squibb/Celgene and Merck Serono/MSD B. A. Senior: Consultant for Stryker, Lyra Therapeutics, and Neuroent S. K. Wise: Consultant for Chitogel, NeurENT, Optinose, and SoundHealth B. A. Woodworth: Consultant for Cook Medical and Medtronic P.-J. Wormald: Royalties from Medtronic, Integra, and Fusetech; consultant for Neilmed and Stryker J. N. Palmer: Consultant for Acclarent and Optinose A. Chua: Consultant for Acclarent and MicrogenDx None of the above conflicts of interest are relevant to the content of ICSNT. The other authors declare no conflicts of interest. ORCID Edward C. Kuan MD, MBA https://orcid.org/0000 0003-3475-0718 Eric W. Wang MD https://orcid.org/0000-0002-1180 5854 Daniel M. Beswick MD https://orcid.org/0000-0001 8612-5442 Marilene B. Wang MD https://orcid.org/0000-0002 2799-6325 Jeremiah A. Alt MD, PhD https://orcid.org/0000-0003 0560-5028 Benjamin S. Bleier MD https://orcid.org/0000-0003 0783-8861 Claudio Callejas MD https://orcid.org/0000-0002-6993 4456 Garret Choby MD https://orcid.org/0000-0002-3745 2727 Gianluca Dalfino MD https://orcid.org/0000-0002 1380-4206